icon
Showing 301 results
  • Outside meeting space on Novartis Campus Basel
    Image
    lock
    Locations / Image
    Outside meeting space on Novartis Campus Basel

    One of many inspiring work environments on Novartis Campus Basel.

  • View of Fabrikstrasse 15, Novartis Campus Basel
    Image
    lock
    Locations / Image
    View of Fabrikstrasse 15, Novartis Campus Basel
  • View of Forum 1 and Fabrikstrasse, Novartis Campus Basel
    Image
    lock
    Locations / Image
    View of Forum 1 and Fabrikstrasse, Novartis Campus Basel
  • Novartis Animated Logo
    Video
    lock
    Corporate Responsibility / B Roll
    Novartis Animated Logo
  • NIBR Cambridge, United states
    Video
    lock
    Manufacturing / B Roll
    NIBR Cambridge, United states
  • NIBR Basel
    Video
    lock
    Manufacturing / B Roll
    NIBR Basel
  • Managing the TSC Transition to Adult Care
    Video
    lock
    Disease Awareness / Video
    Managing the TSC Transition to Adult Care

    Ann describes how to live with symptoms as an adult living with Tuberous Sclerosis Complex (TSC) .

  • Rob Kowalski, Chief People & Organization Officer
    Image
    lock
    Leadership / Image
    Rob Kowalski

    Chief People & Organization Officer since September 1, 2021│Member of the Executive Committee

  • PDF
    lock
    Products / Infographic
    Interleukin 17-A (IL-17A) in Psoriasis

    A cornerstone cytokine (messenger protein) involved in the development of psoriasis and other autoimmune diseases.

  • PDF
    lock
    Products / Infographic
    Interleukin 17-A (IL-17A) in Inflammatory Joint Disease

    IL-17A helps fight infection but in chronic inflammatory joint diseases, IL-17A is a key cytokine involved in disease development.

  • Image
    lock
    Products / Image
    Kymriah® (tisagenlecleucel) suspension for intravenous infusion

    Photo of Kymriah™ (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019.

  • PDF
    lock
    Products / Fact Sheet
    RTH258 Brolucizumab Clinical Trials

    Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.